SU2C receives $4 from Mirati for KRAS mutant cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer will receive a $4 million grant from Mirati Therapeutics Inc. to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst program.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login